One in three Australians suffer from poor quality sleep. New research suggests sleep deprivation is costing the Australian economy more than $5.1 billion a year in both direct and indirect costs.
Many people with asthma have sensitivities to certain drugs that can precipitate an asthma attack. If you have asthma, you need to be aware of which medications may be triggers. You do not need to avoid these medications unless you know they are asthma triggers for you. If these medications have never triggered your asthma, it is still best to take the medications with caution because a reaction can occur at any time.
1 in 2 Australians will be diagnosed with cancer by the age of 85, with more than 60% of cancer patients surviving more than five years after diagnosis.According to a recent US study the hidden psychological scars caused by the diagnosis of cancer can leave scaring akin to that inflicted by war, with the impact in some cases lasting for years.Patients needed for patent 1, patent 2 and chest clinical trials
PATENT 1, PATENT 2 and CHEST trials are currently underway at the Wesley Pulmonary Hypertension Unit and new patients are required. We are trialing Riociuguat - a direct stimulator of the soluable Guanylate Cyclase which plays a significant role in the nitric oxide pathway and is intended for the treatment of PH. The trial is in association with Bayer and Wesley Research Institute.
In PATENT 1 & 2 trials, the patient can already be on therapy with an endothelin receptor antagonists (bosentan, sitaxentan or ambrisetan) or naïve to PAH therapy.
The CHEST trial is using the same agent for non-operable chronic thromboembolic disease related PAH. (CTEPH)
We are accepting patients now for these trials by referral.
About The Wesley Pulmonary Hypertension Unit
The Wesley Pulmonary Hypertension Unit (WPHU) has established itself as one of the largest specialised treatment centres in Queensland. In just 18 months of operation, the clinic has reviewed patients for treatment and have been actively enrolling patients into international clinical trials. The treatment programs include monotherapy and combination treatments in keeping with the best available therapies for PAH.
|
Treatments Available All PBS funded medications for monotherapy Combination therapy – funded or via clinical trials |
Clinical Trials with WRI PATENT 1 and 2 trials CHEST trial |
Diagnostic Procedures Cardiac Catherterisation |
The Wesley Pulmonary Hypertension Unit multidisciplinary team includes:
Dr John Feenstra
Thoracic and Sleep Physician
P: (07) 3876 9033
F: (07) 3871 3222
E:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
W: www.thoracicandsleep.com.au
Dr Andrew Scott
Thoracic and Sleep Physician
P: (07) 3876 8405
F: (07) 3870 3212
E:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
W: www.thoracicandsleep.com.au
Dr David Cross
Cardiologist
P: (07) 3858 8600
F: (07) 3870 4917
E:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
W: www.heartcarepartners.com.au
Helen Woodhouse, CNC
WPHU Coordinator
P: 0404 650 281
F: (07) 3871 3222
E:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it